P-wave widening on the 12-lead electrocardiogram denotes abnormal atrial depolarization and has been shown to be associated with myocardial ischemia during treadmill exercise tolerance testing. However, its true significance during dipyridamole (Persantine) stress imaging remains questionable given the potential direct as well as indirect effects of dipyridamole on the atria. We present a novel series of 5 comparable cases of dipyridamole stress imaging where serial P-wave duration increase occurred during administration of dipyridamole. We observed that such P-wave widening occurred even in the absence of evidence of myocardial ischemia on subsequent myocardial perfusion imaging. Clinicians should therefore be aware of this potential association where, unlike that observed with graded exercise treadmill testing, P-wave widening during dipyridamole infusion could perhaps be a pharmacological effect on the atria instead of an indication of underlying myocardial ischemia.

Keywords:
Dipyridamole stress imaging, Adverse effect, P-wave widening, Atrial depolarization abnormality
1.
Lette J, Tatum JL, Fraser S, Miller DD, Waters DD, Heller G, Stanton EB, Bom HS, Leppo J, Nattel S: Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study. J Nucl Cardiol 1995;2:3–17.
2.
Goyal SB, Spodick DH: Electromechanical dysfunction of the left atrium associated with interatrial block. Am Heart J 2001;142:823–827.
3.
Pandya A, Ellestad MH, Crump R: Time course of changes in P-wave duration during exercise. Cardiology 1996;87:343–346.
4.
Pennell DJ, Ell PJ: Atrial fibrillation after intravenous dipyridamole for thallium imaging. Eur J Nucl Med 1992;19:1064–1065.
5.
Lo Mauro R, Sabella FP, Enia F: Sinus arrest associated with dipyridamole infusion. Int J Cardiol 1990;27:272–274.
6.
Frossard M, Weiss K, Gossinger H, Zeiner A, Leitha T: Asystole during dipyridamole infusion in patients without coronary artery disease or beta-blocker therapy. Clin Nucl Med 1997;22:97–100.
7.
Bielen M, Karsera D, Melon P, Kulbertus H: Severe bradyarrhythmia during myocardial perfusion scintigraphy with injection of dipyridamole (Persantine). Rev Med Liege 1999;54:105–108.
8.
Pennell DJ, Underwood SR, Ell PJ: Symptomatic bradycardia complicating the use of intravenous dipyridamole for thallium-201 myocardial perfusion imaging. Int J Cardiol 1990;27:272–274.
9.
American Society of Nuclear Cardiology: Imaging Guidelines for Nuclear Cardiology Procedures/Guidelines and Standards. 2007. http://www.asnc.org/section_73.cfm (accessed April 9, 2007).
10.
Ariyarajah V, Apiyasawat S, Spodick DH: Association of Duke prognostic treadmill scores with change in P-wave duration during exercise tolerance tests in patients with interatrial block and coronary heart disease. Am J Cardiol 2006;98:786–788.
11.
Dilaveris PE, Andrikopoulos GK, Metaxas G, Richter DJ, Avgeropoulou CK, Androulakis AM, Gialafos EJ, Michaelides AP, Tou-touzas PK, Gialafos JE: Effects of ischemia on P wave dispersion and maximum P wave duration during spontaneous anginal episodes. Pacing Clin Electrophysiol 1999;22:1640–1647.
12.
Myrianthefs MM, Ellestad MH, Startt-Selvester RH, Crump R: Significance of signal-averaged P-wave changes during exercise in patients with coronary artery disease and correlation with angiographic findings. Am J Cardiol 1991;68:1619–1624.
13.
Apiyasawat S, Thomas AJ, Spodick DH: Interatrial block during exercise tolerance tests as an additional parameter for the diagnosis of ischemic heart disease. J Electrocardiol 2005;38:150–153.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.